Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus lenvatinib for unresectable cutaneous angiosarcoma
jRCT2031240448Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in cutaneous angiosarcoma, sponsored by Merck & Co. Primary endpoint: objective response rate. Started Mar 2025; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
cutaneous angiosarcoma
Beyond the preview
Go deeper on jRCT2031240448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240448.